Trial Profile
A first-in-human study of a cell division inhibitor (ESP-01) for the treatment of multiple types of cancers
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 May 2015
Price :
$35
*
At a glance
- Drugs ESP 01 (Primary)
- Indications Advanced breast cancer; Cancer; Colorectal cancer; Ovarian cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- 20 May 2015 New trial record
- 13 Apr 2015 Esperas plans to initiate this study in the first quarter of 2016.